Clinical Trials

Human clinical trial commences for first leprosy vaccine candidate

The Infectious Disease Research Institute (IDRI) and American Leprosy Missions have started a Phase 1 clinical trial in humans for leprosy vaccine candidate, the first vaccine developed specifically for leprosy.

Ardelyx’s phase 3 study of Tenapanor for IBS-C meets primary endpoint

Ardelyx has released positive results from its second Phase 3 study of tenapanor, dubbed T3MPO-2, for irritable bowel syndrome with constipation (IBS-C).

Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto

Bayer, along with its development partner Janssen Research & Development, has halted the phase III Navigate ESUS study of rivaroxaban (Xarelto), as it demonstrated comparable efficacy between treatment arms.

Anthem, HealthCore, Boehringer initiate pragmatic clinical trial to study people living with COPD in real-world setting

The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to study how commonly prescribed medicines may reduce the occurrence of exacerbations of COPD.

Zika vaccine found safe, promising in first human trial

A DNA-based Zika vaccine, dubbed GLS-5700, developed by a consortium led by Inovio Pharmaceuticals and GeneOne Life Science succeeded in a phase 1 clinical trial by producing anti-Zika response in humans.

Motif Bio’s iclaprim meets primary endpoint in second phase 3 ABSSI trial

UK-based Motif Bio reported that its skin disorder drug iclaprim has succeeded in a second phase 3 trial in patients with acute bacterial skin and skin structure infections (ABSSSI).

10,000 to be tested in world’s first trial for universal flu vaccine

NHS patients are taking part in a world-first trial for a universal flu vaccine supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire.

Ablynx’s blood disease drug caplacizumab passes phase 3 aTTP trial

Ablynx's blood disease drug caplacizumab succeeded in a phase 3 trial in patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare autoimmune blood clotting disorder.

Tricida begins phase 3 study of TRC101 to treat metabolic acidosis associated with chronic kidney disease

Tricida announced that the first subject was enrolled in TRCA-301, a phase 3 study evaluating TRC101 in chronic kidney disease (CKD) patients with metabolic acidosis.